NCT02275416View on ClinicalTrials.gov

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 2, 2015

Primary Completion Date

October 6, 2016

Study Completion Date

November 3, 2020

Conditions
Malignant Melanoma
Interventions
DRUG

Ipilimumab

BIOLOGICAL

UV1 vaccine

BIOLOGICAL

GM-CSF

Trial Locations (1)

0379

Oslo University Hospital, Radiumhospitalet, Oslo

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

lead

Ultimovacs ASA

INDUSTRY

NCT02275416 - Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter